Frank E. Young
Young as Commissioner of Food and Drugs
16th Commissioner of Food and Drugs
In office
July 15, 1984 – December 17, 1989
PresidentRonald Reagan
George H. W. Bush
Preceded byArthur H. Hayes Jr.
Succeeded byDavid A. Kessler
Personal details
Born
Frank Edward Young

(1931-09-01)September 1, 1931
Mineola, New York, U.S.
DiedNovember 24, 2019(2019-11-24) (aged 88)
Wilmington, North Carolina, U.S.
Political partyRepublican
Alma materState University of New York Upstate Medical University (MD)
Uniformed service
AllegianceUnited States
Service/branchU.S. Public Health Service Commissioned Corps
Years of service1984–1996
Rank Rear Admiral[1]

Frank Edward Young (September 1, 1931 – November 24, 2019) was an American physician who served as Commissioner of Food and Drugs from 1984 to 1989[2] and later as a deputy assistant secretary in the United States Department of Health and Human Services.[3] In 2013 he joined Braeburn Pharmaceuticals as executive vice president, clinical and regulatory affairs.[4] In 2018, he became the executive vice president of clinical and regulatory affairs at TissueTech Inc.[5]

Education

Young received an M.D. degree (cum laude) from the State University of New York Upstate Medical Center in Syracuse in 1956 and a Ph.D. in microbiology from Western Reserve University in Cleveland, Ohio, in 1962.[6]

Medical career

Young completed his residency in pathology at the University Hospitals, Western Reserve University. He went on to become chairman of the Department of Microbiology and professor of microbiology, pathology and radiation biology and biophysics at the University of Rochester. Before his appointment as Commissioner of the Food and Drug Administration, he was dean of the School of Medicine and Dentistry and vice president for health affairs at the University of Rochester.[7]

Tenure as FDA Commissioner

Young was sworn in as Commissioner of the Food and Drug Administration by Secretary of Health and Human Services Margaret Heckler on August 2, 1984. During his tenure, Young presided over several major agency events, including the Drug Price Competition and Patent Term Restoration Act (1984), passage of the Prescription Drug Marketing Act (1987), approval of the first drug to combat AIDS, zidovudine (AZT) (1987), development of the treatment use of Investigational New Drugs (IND) for the desperately ill, such as people with AIDS, cancer and heart disease (1988); managing the generic drug crisis (1989),[8] during which three officials of the Food and Drug Administration pleaded guilty to receiving bribes, and two manufacturers of generic drugs admitted to providing false data,[9] and the 1989 Chilean grape scare, where Chilean grapes were temporarily banned by the FDA because of a threat and the discovery of two cyanide-tainted grapes.


After the FDA

Young left the FDA in 1989 to become Deputy Assistant Secretary for Health, Science, and Environment under Health and Human Services Secretary Louis Wade Sullivan. Subsequently, Young served as director of both the Office of Emergency Preparedness and the National Disaster Medical System during the Clinton Administration, from 1993 until his retirement from federal service in 1996.[10]

In 2013, Young joined Braeburn Pharmaceuticals as executive vice president, clinical and regulatory affairs to contribute to the development of the new drug application (NDA) to FDA for evaluation of Braeburn’s Probuphine (buprenorphine) implant, which was approved on May 26, 2016.[11] Probuphine is the first buprenorphine implant for the maintenance treatment of opioid dependence.[12]

Young has advised numerous pharmaceutical companies on regulatory issues and clinical development. He served as interim vice president for clinical and regulatory affairs of Bioventus Global and became an adjunct partner and partner at Essex Woodlands in 2002. He also co-founded the Cosmos Alliance and served as its chairman and chief executive officer.[13]

He served as the executive vice president of clinical and regulatory affairs at TissueTech Inc, where he was tasked to lead the company in its transition from a HCT/P regulated company into a biologics company through the pursuit of multiple NDAs for ultimate BLA approval.

Awards and achievements

Young contributed to more than 200 scientific publications in the fields of biotechnology and pathology and developed some of the earliest cloning enzymes, vectors, and vehicles. He is a member of the National Academy of Medicine.[14]

At the Department of Health and Human Services, Young received a Secretary’s Special Citation and the Inspector General’s Award for Outstanding Integrity. He also received the Surgeon General’s Exemplary Service Medal from the United States Public Health Service and the 2006 Distinguished Alumnus Award from SUNY Upstate Medical University.[15]

In 2015, Young was awarded the 2015 Distinguished Scientist Award by the American College of Toxicology for his outstanding contributions to toxicology and the improvement of public health.[16]

Personal life

Young was the son of Frank E. and Erma F. Young. He served in the United States Navy in the Ready Reserve from 1956-1964 and retired in 1996 from the Commissioned Corps of the United States Public Health Service as a rear admiral after 12 years of Service.[17] He was married to the former Leanne Hutchinson from 1956 until her death in 2008. They had five children.[18] Young also served as a pastor in the Evangelical Presbyterian Church for approximately six years before retiring as pastor emeritus.[17]

He died of lymphoma on November 24, 2019, in Wilmington, North Carolina at age 88.[19]

References

  1. ↑ "Retirements-August". Commissioned Corps Bulletin. Vol. X, no. 9. Department of Health and Human Services. September 1996. p. 15.
  2. ↑ "Frank E.Young, M.D." Food and Drug Administration. Retrieved 28 May 2017.
  3. ↑ "Frank E.Young M.D .Ph.D." Braeburn Pharmaceuticals. Retrieved 28 May 2017.
  4. ↑ "Dr. Frank Young Braeburn Pharmaceuticals". William Reed Business Media SAS. Retrieved 28 May 2017.
  5. ↑ "TissueTech Appoints Dr. Frank Young Executive Vice President of Regulatory Affairs | TissueTech". tissuetech.com. Retrieved 2019-03-25.
  6. ↑ "Frank E.Young, M.D". Food and Drug Administration. Retrieved 28 May 2017.
  7. ↑ "Frank Young, M.D., Ph.D. Adjunct Partner Houston". Essex Woodlands Healthcare Partners. Retrieved 27 April 2017.
  8. ↑ "Frank E.Young, M.D." Food and Drug Administration. Retrieved 28 May 2017.
  9. ↑ "The Generic Drug Scandal". The New York Times. New York. 2 October 1989. Retrieved 29 May 2017.
  10. ↑ "Frank E. young, M.D." Food and Drug Administration. Retrieved 28 May 2017.
  11. ↑ "FDA approves first buprenorphine implant for treatment of opioid dependence". Food and Drug Administration. Retrieved 29 May 2017.
  12. ↑ "What Is Probuphine (buprenorphine)?". Braeburn Pharmaceuticals. Archived from the original on 6 June 2017. Retrieved 29 May 2017.
  13. ↑ "Frank E. Young, MD, PhD". Braeburn Pharmaceuticals. Retrieved 27 April 2017.
  14. ↑ "Frank E. Young, MD, PhD Biography". American College of Toxicology. Retrieved 27 April 2017.
  15. ↑ "Distinguished-Alumnus-Award" (PDF). Medical Alumni Foundation for Upstate Medical University. Retrieved 27 April 2017.
  16. ↑ "ACT's-36th-Annual-Meeting-Highlight-Series:Award-Ceremony-and-Luncheon". American College of Toxicology. Retrieved 27 April 2017.
  17. 1 2 "Frank E. Young, MD, PhD Biography". American College of Toxicology. Retrieved 18 July 2017.
  18. ↑ "Distinguished-Alumnus-Award" (PDF). Medical Alumni Foundation for Upstate Medical University. Retrieved 18 July 2017.
  19. ↑ Schudel, Matt (2019-11-29). "Frank E. Young, scientist and FDA commissioner in 1980s, dies at 88". The Washington Post. Retrieved 2019-11-30.
Wikimedia Commons has media related to Frank E. Young (physician).
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.